Literature DB >> 23608205

The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates.

Paul E Carlson1, Seth T Walk, Alexandra E T Bourgis, Melissa W Liu, Fatos Kopliku, Eugene Lo, Vincent B Young, David M Aronoff, Philip C Hanna.   

Abstract

Since 2000, Clostridium difficile isolates of ribotype 027 have been linked to outbreaks in North America and Europe and also an increased rate of colectomy and death among infected individuals. It has been proposed that enhanced sporulation and toxin production were associated with this apparent increase in virulence of 027 isolates. Since only a limited number of isolates have been examined, the relationship of these phenotypes to a specific ribotype, and as well as to clinical disease severity, remains controversial. 106 recent clinical isolates from the University of Michigan Health System were characterized for the ability to sporulate, produce viable spores, grow in rich media, and produce toxins in vitro. Significant variation was observed between isolates for each of these phenotypes. Isolates of ribotype 027 produced higher levels of toxin and exhibited slower growth compared to other ribotypes. Importantly, increased spore production did appear to be relevant to severe C. difficile infection, as determined by available clinical meta-data. These data provide the first significant difference between isolates from severe vs. less severe disease based on an in vitro C. difficile phenotype and suggest that clinical outcome is better predicted by bacterial attributes other than ribotype.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Clostridium difficile; NAP1/027; Ribotype; Sporulation

Mesh:

Substances:

Year:  2013        PMID: 23608205      PMCID: PMC4038106          DOI: 10.1016/j.anaerobe.2013.04.003

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  24 in total

1.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.

Authors:  Thomas Akerlund; Ingela Persson; Magnus Unemo; Torbjörn Norén; Bo Svenungsson; Marlene Wullt; Lars G Burman
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

4.  Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.

Authors:  S Karlsson; A Lindberg; E Norin; L G Burman; T Akerlund
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids.

Authors:  Sture Karlsson; Lars G Burman; Thomas Åkerlund
Journal:  Microbiology       Date:  1999-07       Impact factor: 2.777

Review 6.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

7.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

8.  Repression of Clostridium difficile toxin gene expression by CodY.

Authors:  Sean S Dineen; Anuradha C Villapakkam; Jared T Nordman; Abraham L Sonenshein
Journal:  Mol Microbiol       Date:  2007-08-28       Impact factor: 3.501

9.  Effect of isoleucine on toxin production by Clostridium difficile in a defined medium.

Authors:  D Ikeda; T Karasawa; K Yamakawa; R Tanaka; M Namiki; S Nakamura
Journal:  Zentralbl Bakteriol       Date:  1998-05

10.  Microevolutionary analysis of Clostridium difficile genomes to investigate transmission.

Authors:  Xavier Didelot; David W Eyre; Madeleine Cule; Camilla L C Ip; M Azim Ansari; David Griffiths; Alison Vaughan; Lily O'Connor; Tanya Golubchik; Elizabeth M Batty; Paolo Piazza; Daniel J Wilson; Rory Bowden; Peter J Donnelly; Kate E Dingle; Mark Wilcox; A Sarah Walker; Derrick W Crook; Tim E A Peto; Rosalind M Harding
Journal:  Genome Biol       Date:  2012-12-21       Impact factor: 13.583

View more
  43 in total

1.  Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality.

Authors:  Krishna Rao; Dejan Micic; Mukil Natarajan; Spencer Winters; Mark J Kiel; Seth T Walk; Kavitha Santhosh; Jill A Mogle; Andrzej T Galecki; William LeBar; Peter D R Higgins; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2015-03-31       Impact factor: 9.079

2.  Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology.

Authors:  Jonathan N V Martinson; Susan Broadaway; Egan Lohman; Christina Johnson; M Jahangir Alam; Mohammed Khaleduzzaman; Kevin W Garey; Jessica Schlackman; Vincent B Young; Kavitha Santhosh; Krishna Rao; Robert H Lyons; Seth T Walk
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

Review 3.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

4.  Editorial commentary: Host-pathogen interactions in Clostridium difficile infection: it takes two to tango.

Authors:  David M Aronoff
Journal:  Clin Infect Dis       Date:  2014-03-05       Impact factor: 9.079

5.  N-Deacetylases required for muramic-δ-lactam production are involved in Clostridium difficile sporulation, germination, and heat resistance.

Authors:  Héloise Coullon; Aline Rifflet; Richard Wheeler; Claire Janoir; Ivo Gomperts Boneca; Thomas Candela
Journal:  J Biol Chem       Date:  2018-09-28       Impact factor: 5.157

Review 6.  Clostridioides difficile Spores: Bile Acid Sensors and Trojan Horses of Transmission.

Authors:  Aimee Shen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

Review 7.  Clostridium difficile Infection: An Epidemiology Update.

Authors:  Ana C De Roo; Scott E Regenbogen
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

Review 8.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

9.  Variation in germination of Clostridium difficile clinical isolates correlates to disease severity.

Authors:  Paul E Carlson; Alyssa M Kaiser; Sarah A McColm; Jessica M Bauer; Vincent B Young; David M Aronoff; Philip C Hanna
Journal:  Anaerobe       Date:  2015-02-11       Impact factor: 3.331

Review 10.  Clostridium Difficile Infection from a Surgical Perspective.

Authors:  Andreas M Kaiser; Rachel Hogen; Liliana Bordeianou; Karim Alavi; Paul E Wise; Ranjan Sudan
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.